Phytonadione tablets center on vitamin K replacement, not rapid clot reversal
Phytonadione tablets remain a narrow but important oral option for adults whose coagulation defects stem from vitamin K deficiency or interference with vitamin K activity. The updated DailyMed label keeps the focus on a familiar set of indications: anticoagulant-induced prothrombin deficiency from coumarin or indanedione derivatives, hypoprothrombinemia after antibacterial therapy, and deficiency states tied to impaired absorption or synthesis of vitamin K. Obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis are all explicitly named because each can reduce the body’s access to the fat-soluble vitamin needed to build functional clotting factors.
The mechanism is straightforward, but the bedside consequences are not. Vitamin K replacement helps the liver resume production of factors II, VII, IX, and X, yet the effect is delayed rather than immediate. The label states that improvement in the INR may take 1 to 8 hours, which matters in any patient with active bleeding or a rapidly changing coagulation profile. When bleeding is severe, whole blood or component therapy may still be needed while the vitamin K effect develops.
A single tablet does not solve every coagulopathy.
Oral dosing depends on the cause, the INR, and how well the gut can absorb the drug
The prescribing information gives separate adult dosing ranges for anticoagulant-induced prothrombin deficiency and for hypoprothrombinemia from other causes. For excessively prolonged prothrombin times related to oral anticoagulant therapy, the recommended starting dose is 2.5 mg to 10 mg, with doses up to 25 mg initially and, in some instances, 50 mg. If the prothrombin time has not shortened satisfactorily within 12 to 48 hours after oral administration, another dose can be given. Subsequent frequency and amount should follow the prothrombin time response or the clinical condition.
For hypoprothrombinemia from other causes, the label recommends 2.5 mg to 25 mg or more, sometimes up to 50 mg. INR should be checked after 6 to 8 hours, and repeat dosing is guided by the persistence of prolongation. The label also advises stopping or reducing interacting drugs when possible, especially salicylates and antibiotics, before or alongside phytonadione treatment. In practice, that reflects a basic pharmacologic truth: if the offending agent remains present, the clotting defect may persist even after replacement therapy is started.
Absorption issues receive unusually direct attention. Oral therapy should be avoided when the clinical disorder would prevent proper absorption, and bile salts must be given with the tablets when endogenous bile delivery to the gastrointestinal tract is deficient. Since vitamin K is fat-soluble, impaired bile flow can make oral replacement unreliable. A patient with cholestatic disease may swallow the tablet and still fail to absorb enough drug to normalize clotting factor production.
The label warns against treating vitamin K like a clotting agent
One of the most clinically important lines in the label is also one of the easiest to overlook: phytonadione is not a clotting agent. It restores the biochemical capacity to make clotting factors; it does not directly replace those factors in the moment. When oral anticoagulant therapy is still indicated, reversal also reintroduces the thromboembolic risk that existed before anticoagulation began. The label explicitly warns that overzealous vitamin K1 use may restore conditions that originally permitted thromboembolic phenomena, which is why the dose should be kept as low as possible and the prothrombin time checked regularly.
The warning is especially relevant in patients whose elevated INR reflects a medication effect rather than an intrinsic bleeding disorder. Reducing the INR too aggressively can overshoot the therapeutic balance and leave the patient vulnerable to thrombosis. In that sense, dose selection is not simply a question of correction; it is an attempt to move the coagulation system back toward a safer middle ground without forcing it past the point of intended anticoagulation.
Repeated large doses are not warranted in liver disease if the initial response is poor. Failure to respond can point to a congenital coagulation defect or to a disorder that does not respond to vitamin K at all, which is an important diagnostic clue rather than a reason to keep escalating the drug indefinitely.
Hypersensitivity and transient cardiovascular reactions remain part of the safety profile
The tablet is contraindicated in patients with a history of hypersensitivity to phytonadione or inactive ingredients. The adverse reaction profile on the label is concise but clinically relevant. Most common reactions include transient flushing sensations, unusual taste, dizziness, rapid and weak pulse, profuse sweating, brief hypotension, dyspnea, and cyanosis. These effects are especially familiar from parenteral phytonadione, but they remain part of the safety discussion across formulations because they signal the potential for acute intolerance in susceptible patients.
The drug interaction section also reinforces a practical point for everyday prescribing: phytonadione may induce temporary resistance to prothrombin-depressing anticoagulants. For clinicians, that means the response after reversal can be unstable over time, particularly if anticoagulation is resumed too quickly or if follow-up INR checks are delayed. The label’s advice to monitor prothrombin time regularly is not a formality; it is the mechanism by which clinicians avoid both undertreatment and overshoot.
The product description itself is modest: 5 mg light yellow to yellow, round, uncoated tablets engraved with “10 14” on one side and a break line on the other. The formulation details are not the main story, but they do matter when an oral vitamin K product is selected to address a bleeding risk that may be driven by malabsorption, antibiotics, or warfarin-like anticoagulation. In those settings, the tablet is a correction tool, not an emergency antidote, and the timing of laboratory reassessment determines whether the dose has done enough or whether the patient needs a different approach.